Antibody-mediated neutralization of CXCL9 during established obesity conferred protection from hepatocellular damage (51), suggesting that activating the CXCL9 axis may represent an essential hallmark of MASLD progression. Here, CXCL9 is linked to metabolic dysfunction-associated steatotic liver disease.